InMed Pharmaceuticals Past Earnings Performance

Past criteria checks 0/6

InMed Pharmaceuticals has been growing earnings at an average annual rate of 2.7%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 71.5% per year.

Key information

2.7%

Earnings growth rate

45.0%

EPS growth rate

Pharmaceuticals Industry Growth7.3%
Revenue growth rate71.5%
Return on equity-81.2%
Net Margin-137.4%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How InMed Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:MWG Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 245-753
30 Jun 245-854
31 Mar 246-653
31 Dec 235-653
30 Sep 235-764
30 Jun 234-864
31 Mar 232-1565
31 Dec 222-1765
30 Sep 221-1977
30 Jun 221-1977
31 Mar 221-1477
31 Dec 210-1468
30 Sep 210-1256
30 Jun 210-1045
31 Mar 210-935
31 Dec 200-734
30 Sep 200-835
30 Jun 200-936
31 Mar 200-1047
31 Dec 190-1157
30 Sep 190-1056
30 Jun 190-1064
31 Mar 190-963
31 Dec 180-862
30 Sep 180-762
30 Jun 180-651
31 Mar 180-641
31 Dec 170-541
30 Sep 170-541
30 Jun 170-331
31 Mar 170-220
31 Dec 160-210
30 Sep 160-210
30 Jun 160-210
31 Mar 160-321
31 Dec 150-321
30 Sep 150-321
30 Jun 150-331
31 Mar 150-331
31 Dec 140-220
30 Sep 140-220
30 Jun 140-110
31 Mar 140000

Quality Earnings: MWG is currently unprofitable.

Growing Profit Margin: MWG is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: MWG is unprofitable, but has reduced losses over the past 5 years at a rate of 2.7% per year.

Accelerating Growth: Unable to compare MWG's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MWG is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (25.4%).


Return on Equity

High ROE: MWG has a negative Return on Equity (-81.19%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 16:20
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

InMed Pharmaceuticals Inc. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullBrookline Capital Markets
Raghuram SelvarajuH.C. Wainwright & Co.
Jason McCarthyMaxim Group